首页> 美国卫生研究院文献>BMC Cancer >Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

【2h】

Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

机译：患有FDG-PET的SUVMAX的组合预后值和IIIB-IV阶段非小细胞肺癌接受化疗的患者淋巴细胞单核细胞比例

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Baseline characteristics of 149 patients

机译：149名患者的基线特征

著录项

期刊名称 BMC Cancer
作者
Kewei Zhao; Chunsheng Wang; Fang Shi; Yong Huang; Li Ma; Minghuan Li; Yipeng Song;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 13
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Non-small cell lung cancer; Maximum standardized uptake value; Lymphocyte-monocyte ratio; Response; Survival;

机译：非小细胞肺癌;最大标准化摄取值;淋巴细胞单核细胞比例;反应;生存;

相似文献

外文文献
中文文献
专利

1. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy [J] . Kewei Zhao, Chunsheng Wang, Fang Shi, BMC Cancer . 2021,第1期

机译：源自FDG-PET的SUVMAX的组合预后值和IIIB-IV阶段非小细胞肺癌接受化疗的患者淋巴细胞单核细胞比
2. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. [J] . Imamura Y, Azuma K, Kurata S, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2011,第1期

机译：通过FDG-PET获得的SUVmax测量值对接受化疗的非小细胞肺癌患者的预后价值。
3. Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations [J] . Xing Li, Wei-Hua Zeng, Yu-Qi Zhou, OncoTargets and therapy . 2019,第2期

机译：中性粒细胞与淋巴细胞的比例可预测无敏感突变的IIIB-IV期非鳞状非小细胞肺癌患者的长期化疗获益
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations [O] . Xing Li, Wei-Hua Zeng, Yu-Qi Zhou, 2019

机译：中性粒细胞与淋巴细胞的比例可预测无敏感突变的IIIB-IV期非鳞状非小细胞肺癌患者的长期化疗益处
7. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis [O] . Ie Ryung Yoo, Soo Kyo Chung, Hye Lim Park, 2014

机译：早期非小细胞肺癌患者18F-FDG PET / CT对18F-FDG PET / CT的预后价值，没有LN转移

Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅